ReviewCurrent opinion in endocrinology, diabetes, and obesity2014
Targeted immune interventions for type 1 diabetes: not as easy as it looks!
Review in Current opinion in endocrinology, diabetes, and obesity, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 24 citations in OpenAlex.
- Trial
- Elevated T cell levels in peripheral blood predict poor clinical response following rituximab treatment in new-onset type 1 diabetes.Genes and immunity · 2019Trial
- Hydrogel-based approaches to target hypersensitivity mechanisms underlying autoimmune disease.Advanced drug delivery reviews · 2024Review
- Germline-like TCR-α chains shared between autoreactive T cells in blood and pancreas.Nature communications · 2024Article
- A hydrogel platform for co-delivery of immunomodulatory proteins for pancreatic islet allografts.Journal of biomedical materials research. Part A · 2022Article
- Approaches to Inducing β-Cell Regeneration.Biomedicines · 2022Review
- TIGIT as a Promising Therapeutic Target in Autoimmune Diseases.Frontiers in immunology · 2022Review
- Autoreactive T cell receptors with shared germline-like α chains in type 1 diabetes.JCI insight · 2021Article
- Current Status on Immunological Therapies for Type 1 Diabetes Mellitus.Current diabetes reports · 2019Review
- B lymphocyte alterations accompany abatacept resistance in new-onset type 1 diabetes.JCI insight · 2019Article
- Serum biomarkers for diagnosis and prediction of type 1 diabetes.Translational research : the journal of laboratory and clinical medicine · 2018Review
- Alpha-1 antitrypsin treatment of new-onset type 1 diabetes: An open-label, phase I clinical trial (RETAIN) to assess safety and pharmacokinetics.Pediatric diabetes · 2018Article
- Single-Cell RNA Sequencing Reveals Expanded Clones of Islet Antigen-Reactive CD4Journal of immunology (Baltimore, Md. : 1950) · 2017Article
- Investigation of coordination and order in transcription regulation of innate and adaptive immunity genes in type 1 diabetes.BMC medical genomics · 2017Article
- Partial exhaustion of CD8 T cells and clinical response to teplizumab in new-onset type 1 diabetes.Science immunology · 2016Article
- The Hypoglycaemia-Hyperglycaemia Minimizer System in the Management of Type 1 Diabetes.European endocrinology · 2016Review
- Immune interventions to preserve β cell function in type 1 diabetes.Journal of investigative medicine : the official publication of the American Federation for Clinical Research · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
purpose of reviewAlthough insulin is lifesaving and sustaining for those with type 1 diabetes (T1D), curing the disease will be much more complex than simple replacement of this hormone. T1D is an autoimmune disease orchestrated by T cells, and includes many arms of the immune response. Tremendous effort has gone into understanding its underlying immune, genetic, and environmental causes, and this progress has led to immunologically based clinical trials in T1D. This review will focus primarily on the clinical trials of the past decade that have attempted to translate these fundamental findings. RECENT
findingsIt is known that powerful, nonspecific immune suppressants can temporarily slow the course of newly diagnosed T1D, yet are too toxic for long-term use, especially in children. Recent clinical trials to reverse T1D have used newly developed therapies that target specific components of the immune process believed to be involved with T1D. Although well justified and designed, no recent approach has resulted in clinical remission and few have had any effect on disease course. SUMMARY: Advances in our fundamental understanding of how the human diabetes immune response is activated and regulated coupled with lessons that have been learnt from the most recent era of completed trials are guiding us toward the development of more effective, multipronged therapies to ablate diabetes autoimmunity, restore immune tolerance, preserve β cells, and, ultimately, improve the lives of patients with T1D.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.